The activated ERK signaling could directly or indirectly modulate cell cycle-related proteins, such as CDKs and cyclins controlling G1–S transition phase and pro-metastatic factors, such as EMT markers and MMPs, as well as some cancer stem cell-related genes, such as CD44 and NANOG19–23. The gene discussed is CD44; the disease is cancer.